Login to Your Account

Financings Roundup

NGM's Series C Garners $50M for Ongoing Work in Diabetes

By Randy Osborne
Staff Writer

Friday, July 19, 2013
With a handful of collaborations already under way, NGM Biopharmaceuticals Inc. raised $50 million in a Series C round to advance in-house efforts in cardiometabolic diseases, including diabetes and obesity.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription